Table 3.
Treatment in both groups.
| Parameter {n (%)} | Total (n = 1040) |
Survivors (n = 770) |
Non-Survivors (n = 270) |
p-Value |
|---|---|---|---|---|
| Remdesivir (n, %) | 178 (17.1) | 154 (20) | 24 (8.9) | <0.0001 |
| Tocilizumab (n, %) | 92 (8.8) | 65 (8.4) | 27 (10) | 0.4378 |
| Antibiotic treatment (n, %) | 952 (91.5) | 684 (88.8) | 268 (99.2) | <0.0001 |
| Anticoagulants (n, %) | 1006 (96.7) | 743 (96.5) | 263 (97.4) | 0.4675 |
| Steroids (n, %) | 845 (81.3) | 599 (77.8) | 246 (91.1) | <0.0001 |
| Convalescent plasma (n, %) | 315 (30.3) | 263 (34.2) | 52 (19.3) | <0.0001 |
| Oxygen therapy (n, %) | 929 (89.3) | 661 (85.8) | 268 (99.2) | <0.0001 |
| NIV (n, %) | 131 (12.6) | 64 (8.3) | 67 (24.8) | <0.0001 |
| Ventilator therapy (n, %) | 160 (15.4) | 33 (4.3) | 127 (47) | <0.0001 |
NIV—noninvasive ventilation.